![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, December 06, 2022 11:18:20 AM
1/27/2021 Steven B Ketchum Insider Sell 421,629 $8.01 $3,377,248.29 556,893
11/30/2020 David M Stack Director Buy 25,000 $4.86 $121,500.00
11/10/2020 John F Thero CEO Sell 153,840 $4.13 $635,359.20 2,691,144
11/19/2019 John F Thero CEO Sell 274,454 $20.91 $5,738,833.14
11/12/2019 Lars Ekman Director Sell 38,600 $24.02 $927,172.00
11/11/2019 John F Thero CEO Sell 475,546 $24.02 $11,422,614.92
9/3/2019 Lars Ekman Director Sell 91,016 $15.01 $1,366,150.16 13,500
7/11/2019 David M Stack Director Sell 51,991 $22.28 $1,158,359.48
7/5/2019 Joseph S Zakrzewski Director Sell 100,000 $23.82 $2,382,000.00
7/3/2019 Aaron Berg Insider Sell 98,814 $21.30 $2,104,738.20
7/1/2019 Joseph T Kennedy General Counsel Sell 54,186 $19.52 $1,057,710.72
7/1/2019 Michael Wayne Kalb CFO Sell 50,000 $19.67 $983,500.00
6/24/2019 Aaron Berg Insider Sell 113,195 $18.59 $2,104,295.05
6/18/2019 Joseph S Zakrzewski Director Sell 100,000 $19.02 $1,902,000.00
5/31/2019 Joseph T Kennedy General Counsel Sell 27,229 $17.92 $487,943.68
5/29/2019 David M Stack Director Sell 33,799 $18.45 $623,591.55
5/17/2019 David M Stack Director Sell 13,174 $18.00 $237,132.00
4/30/2019 Joseph T Kennedy General Counsel Sell 27,230 $18.69 $508,928.70
4/30/2019 Steven B Ketchum Insider Sell 9,541 $18.67 $178,130.47
4/1/2019 Joseph T Kennedy General Counsel Sell 54,172 $20.05 $1,086,148.60
4/1/2019 Steven B Ketchum Insider Sell 9,542 $20.06 $191,412.52
3/4/2019 John F Thero Insider Sell 250,000 $21.31 $5,327,500.00
3/4/2019 Lars Ekman Director Sell 135,377 $21.31 $2,884,883.87
3/1/2019 Michael Wayne Kalb CFO Sell 100,000 $22.09 $2,209,000.00
3/1/2019 Steven B Ketchum Insider Sell 55,543 $21.85 $1,213,614.55
2/28/2019 Joseph T Kennedy General Counsel Sell 27,231 $20.72 $564,226.32
2/22/2019 Kristine Peterson Director Sell 163,500 $20.02 $3,273,270.00
2/22/2019 Michael Wayne Kalb CFO Sell 50,000 $18.97 $948,500.00
2/15/2019 Michael Wayne Kalb CFO Sell 25,000 $17.58 $439,500.00
2/1/2019 Steven B Ketchum Insider Sell 37,530 $17.17 $644,390.10
1/31/2019 Joseph T Kennedy General Counsel Sell 42,624 $17.49 $745,493.76
1/24/2019 Joseph T Kennedy General Counsel Sell 1,040,194 $17.77 $18,484,247.38
1/11/2019 Joseph T Kennedy General Counsel Sell 3,173 $18.92 $60,033.16
1/10/2019 Lars Ekman Director Sell 140,416 $17.28 $2,426,388.48
1/9/2019 Michael Wayne Kalb CFO Sell 200,000 $15.26 $3,052,000.00
1/2/2019 Joseph S Zakrzewski Director Sell 526,500 $13.07 $6,881,355.00
12/31/2018 Joseph T Kennedy General Counsel Sell 26,943 $13.49 $363,461.07
12/31/2018 Steven B Ketchum Insider Sell 17,041 $13.51 $230,223.91
11/30/2018 Joseph T Kennedy General Counsel Sell 23,306 $17.81 $415,079.86
11/30/2018 Steven B Ketchum Insider Sell 17,042 $17.79 $303,177.18
11/12/2018 John F Thero Insider Sell 607,611 $19.07 $11,587,141.77
10/31/2018 Joseph T Kennedy General Counsel Sell 23,307 $20.74 $483,387.18
10/31/2018 Steven B Ketchum Insider Sell 17,042 $20.74 $353,451.08
10/1/2018 Joseph T Kennedy General Counsel Sell 50,249 $16.81 $844,685.69
10/1/2018 Steven B Ketchum Insider Sell 316,604 $16.13 $5,106,822.52
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM